
-
Praxis Precision Medicines NasdaqGS:PRAX Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Location: 99 High Street, Boston, MA, 02110, United States | Website: https://praxismedicines.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
456.3M
Cash
328M
Avg Qtr Burn
-40.98M
Short % of Float
11.97%
Insider Ownership
0.16%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ulixacaltamide (PRAX-944) (T-type calcium channel blocker) Details Essential tremor | Phase 3 Data readout | |
Vormatrigine (PRAX-628) Details Epilepsy, Focal Onset Seizures | Phase 2/3 Data readout | |
Phase 2b Data readout | ||
Vormatrigine (PRAX-628) Details Epilepsy, Focal Onset Seizures | Phase 2b Update | |
PRAX-562 Details Developmental and Epileptic Encephalopathy | Phase 2 Data readout | |
Ulixacaltamide (PRAX-944) (T-type calcium channel blocker) Details Parkinson's disease | Phase 2 Update | |
PRAX-222 Details Developmental and Epileptic Encephalopathy | Phase 1/2 Data readout | |
PRAX-114 (GABAA receptor PAM) Details Perimenopausal Depression | Failed Discontinued | |
PRAX-114 (GABAA receptor PAM) Details Major depressive disorder | Failed Discontinued |